AMPK stands for AMP-activated protein kinase. It is an enzyme that acts as the cell’s fuel gauge. When energy runs low, AMPK switches on. When energy is plentiful, it stays quiet.

The name describes how it works. AMP is what is left after the cell spends its ATP. Rising AMP means the tank is emptying. AMPK reads that signal.

Once active, AMPK does two things at once. It turns on the processes that make energy, including glucose uptake and fat burning. At the same time it slows the processes that spend it, such as making new fat and cholesterol.

That dual action is why AMPK appears in research on diabetes, obesity, exercise and insulin resistance. It sits at the point where energy supply and energy demand are balanced (Herzig and Shaw, 2018).

AMPK is built from three subunits, called alpha, beta and gamma. The gamma subunit is the sensor. It has binding sites that hold either AMP or ATP.

When ATP is plentiful, ATP occupies those sites and AMPK stays inactive. When ATP is spent and AMP rises, AMP displaces it. That change alters the shape of the enzyme and makes it far easier to switch on.

This is worth being precise about. AMPK does not read blood sugar. It reads the ratio of AMP to ATP inside the cell. A person can have normal blood glucose and still have cells running low on energy.

Two further points matter. Activation is amplified by an upstream enzyme called LKB1. And AMPK activity is not all or nothing. It scales with how far the ratio has shifted (Steinberg and Hardie, 2023).

Four things reliably raise AMPK activity, and they all work by the same route.

Exercise. Muscle contraction spends ATP quickly. AMP rises and AMPK responds. This is the best evidenced activator by a wide margin.

Fasting and calorie restriction. When incoming fuel drops, the cell draws on stored energy. Fasting raises AMPK activity in a similar way.

Metformin. The prescription drug partially inhibits mitochondrial complex I. That lowers ATP production, raises AMP and activates AMPK. This was one of the first clues to how metformin works (Zhou et al., 2001).

Some plant compounds. Berberine acts on the same mitochondrial target as metformin, though at a different potency (Turner et al., 2008).

The pattern is consistent. Nothing on this list activates AMPK directly. Each one creates an energy shortfall, and AMPK responds to the shortfall.

This is where the standard account becomes incomplete.

Fructokinase (KHK) consumes ATP rapidly and without a brake. By the logic above, that should raise AMP and activate AMPK. In practice, research suggests the opposite happens.

The reason is a second enzyme. AMP deaminase, or AMPD2, also uses AMP. It converts AMP toward uric acid rather than leaving it available to bind AMPK. When AMPD2 activity is high, AMP is cleared before AMPK can read it.

Research indicates fructose shifts the balance toward AMPD2. Uric acid produced downstream has itself been associated with reduced AMPK activity, which would reinforce the shift (Cicerchi et al., 2014).

The proposed result is a cell that is genuinely short of energy but does not mount the usual response. Instead of burning fat to restore ATP, it stores fat. This has been described as a survival mechanism, useful when food was scarce and unhelpful when it is not.

This evidence is largely mechanistic and from animal models. It is a plausible and well argued account rather than a settled human finding.

Exercise. Strong evidence. Both aerobic and resistance training raise AMPK activity, and the effect scales with intensity. Nothing else on this list matches it.

Metformin. Strong evidence, prescription only. Not something to pursue through supplements.

Fasting and calorie restriction. Moderate evidence. Effects are real but vary with duration and individual metabolism.

Berberine. Moderate evidence. It works on the same mitochondrial target as metformin. Absorption is poor and it interacts with several medications, so it warrants medical advice.

Reducing fructose load. Mechanistic evidence. This one is different in kind. Rather than pushing AMPK harder, it addresses a reason the signal may not be reaching AMPK in the first place.

A note on supplement marketing. Many products described as AMPK activators rest on cell culture data. Activating an enzyme in a dish is not the same as changing metabolism in a person. Look for the tier of evidence before the claim.

The strongest levers are the unglamorous ones. Regular physical activity, adequate sleep and a lower added sugar intake all act on the energy balance AMPK is reading.

Two compounds have a mechanism worth naming.

Berberine has moderate human evidence for effects on blood glucose and lipids, acting through the mitochondrial route described above.

Luteolin is being studied for its interaction with fructokinase in preclinical models. The relevance here is indirect. If less ATP is spent on fructose, less AMP is diverted toward uric acid. Evidence is preclinical.

Neither replaces exercise. Both are worth discussing with a healthcare provider, particularly alongside prescribed medication.

At LIV3, we think the interesting question about AMPK is not how to push it harder. It is why the signal sometimes fails to arrive.

If fructose metabolism is diverting AMP toward uric acid before AMPK can read it, then adding another activator treats the symptom. Reducing the diversion addresses the cause.

SugarShield delivers liposomal luteolin alongside tart cherry extract. It is designed to support fructose metabolism at the enzyme where that diversion begins.

SugarShield is a food supplement, not a medicine. It is not intended to diagnose, treat, cure, or prevent any disease.

MASTER GUIDE: The Complete Science of How Fructose Reshapes Your Metabolism

FRUCTOKINASE: The Enzyme That Spends ATP Without a Brake

URIC ACID HUB: Where the Diverted AMP Ends Up

BERBERINE: What the Evidence Shows on Berberine and Blood Glucose

Cicerchi, C., Li, N., Kratzer, J., Garcia, G., Roncal-Jimenez, C. A., Tanabe, K., Hunter, B., Rivard, C. J., Sautin, Y. Y., Gaucher, E. A., Johnson, R. J., & Lanaspa, M. A. (2014). “Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: Evolutionary implications of the uricase loss in hominids.” FASEB Journal, 28(8), 3339-3350.

Herzig, S., & Shaw, R. J. (2018). “AMPK: Guardian of metabolism and mitochondrial homeostasis.” Nature Reviews Molecular Cell Biology, 19(2), 121-135.

Steinberg, G. R., & Hardie, D. G. (2023). “New insights into activation and function of the AMPK.” Nature Reviews Molecular Cell Biology, 24(4), 255-272.

Turner, N., Li, J. Y., Gosby, A., To, S. W., Cheng, Z., Miyoshi, H., Taketo, M. M., Cooney, G. J., Kraegen, E. W., James, D. E., Hu, L. H., Li, J., & Ye, J. M. (2008). “Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I.” Diabetes, 57(5), 1414-1418.

Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., & Moller, D. E. (2001). “Role of AMP-activated protein kinase in mechanism of metformin action.” Journal of Clinical Investigation, 108(8), 1167-1174.